Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496666 | 0.96 | RAB9A (0.66) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL27419824 | 0.84 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL18263482 | 0.84 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10676409 | 0.83 | RAB9A (0.63) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL23742932 | 0.82 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10527876 | 0.82 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL30105286 | 0.82 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1999435 | 0.81 | RAB9A (0.90) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10677526 | 0.80 | RAB9A (0.59) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10673583 | 0.80 | RAB9A (0.56) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2760829-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2013048930-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048930-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049096-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049096-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-1190710-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DIABETES | SHIONOGI & CO., LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | RAB9A 536/4885MAPT 4489/4885SMN1; SMN2 4637/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | RAB9A 536/4885MAPT 4489/4885SMN1; SMN2 4637/4885 |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | RAB9A 2995/4885MAPT 4767/4885SMN1; SMN2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.